Methods of decellularization of tissue, such as mammalian tissue, are provided, along with methods of making an extracellular matrix (ECM) preparation. Systems and apparatus useful in performing the methods are also provided.

The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided.

The present invention relates to a pharmaceutical composition for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide bound to parathyroid hormone (PTH) or a fragment thereof. More particularly, the present invention relates to a pharmaceutical composition and biomaterial for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide represented by an amino acid sequence of SEQ ID NO. 3 bound to parathyroid hormone (PTH) or a fragment thereof represented by an amino acid sequence of SEQ ID NO. 4 or 5. The fusion peptide can improve effects of PTH by selectively binding to bone tissue and can reduce administration frequency by increasing the half-life. The fusion peptide can be used as a subcutaneous or intravenous injection-type pharmaceutical composition for treating osteoporosis and fracture, and can be used in combination with a medical device for tissue recovery to increase formation of bone tissue. In addition, when the fusion peptide is bound to the surface of dental and orthopedic medical devices, transplantation stability of the medical device can be improved through improved osseointegration between the medical device and new bone.

When transplanting a plurality of ovarian tissue fragments, agglomeration of ovarian tissue fragments is prevented, angiogenesis is promoted, and engraftment rate is improved. When transplanting a plurality of ovarian tissue fragments formed by cutting ovarian tissue into a mammal, and the ovarian tissue fragments are transplanted by an injection step in which collagen gel is injected into a site to be transplanted, using collagen gel with a gel concentration of about 1%, and then a transplantation step in which the plurality of ovarian tissue fragments are inserted into the collagen gel. At this time, each of the plurality of ovarian tissue fragments may be previously encapsulated with the collagen gel.

A tympanic construct fabricated from at least one amniotic membrane, at least one chorionic membrane, or at least one amniotic membrane and at least one chorionic membrane obtained from human birth tissue is provided. Methods of preparing a tympanic construct, methods of repairing tympanic membrane defects and surgical sites, as well as kits for the same are also provided.

The invention is a biodegradable polymer composition comprising a particulate biodegradable polymer, particulate extracellular matrix (ECM) derived from a mammalian tissue source, a therapeutic component that abates growth of bacteria and a liquid medium. The biodegradable polymer can change quality upon contact with a physiological parameter, such as temperature or pH that causes, for example, a liquid polymer to gel or harden. The polymer composition is adapted to induce regeneration of tissue in vivo.

Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.

A three-dimensional (3D) biocompatible, degradable soft tissue implant, comprising a bioprinted composite scaffold, the composite scaffold comprising a recombinant human collagen (rhCollagen) and a biocompatible synthetic polymer and features: a porous wall; an inner cavity at least partially enclosed within the porous wall; and at least one injection port that connects the inner cavity with an outer most surface of the scaffold, wherein the injection port has an opening sized to permit insertion of an injection device through the port, processes of preparing same and uses thereof in soft tissue reconstruction are provided. Injectable matrices for use in soft tissue reconstruction, either alone or in combination with the implant are also provided.

Surgical constructs, assemblies, kits and methods of tissue fixation are disclosed. Glenoid augmentation is conducted with one or more soft tissue grafts placed on the anterior glenoid to fill a glenoid defect. Knotted or knotless suture anchors can deliver and fixate the soft tissue graft within the glenoid bone defect. Suture anchors can also secure the native ligament to the soft tissue graft and provide stability to the shoulder joint. Soft suture anchors can deliver and fixate a soft tissue graft within the bone defect. The native soft tissue can be repaired over top of the soft tissue graft into its anatomical position.

A method of forming a substrate includes mapping a three dimensional spatial distribution of at least one structural protein fiber of extracellular matrix of biological material of interest, designing a fiber assembly pattern based on an intrinsic pattern of the at least one structural protein fiber of the extracellular matrix of the biological material, and assembling fibers based on the fiber assembly pattern to form the substrate.